Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysis
Abstract Introduction Although there are a number of neoadjuvant immunotherapy combinations that can be applied to the treatment of perioperative non-small cell lung cancer patients, the optimal treatment combination strategy has not yet been determined. Methods We searched PubMed, EMBASE, Cochrane...
Saved in:
Main Authors: | Linfeng Wang, Guangda Zheng, Yue Hu, Ayidana Maolan, Yue Luo, Yue Li, Rui Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | BMC Pulmonary Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12890-025-03479-2 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Design of studies on neoadjuvant therapy for intrahepatic cholangiocarcinoma
by: Yuan Cheng, et al.
Published: (2025-01-01) -
Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for stage II–IVa esophageal cancer: a network meta-analysis
by: Mingxing Wang, et al.
Published: (2025-01-01) -
Prognostic Impact of Adjuvant Immunotherapy in Patients With Resectable NSCLC After Neoadjuvant Chemoimmunotherapy: A Brief Report
by: Yichen Dong, MD, et al.
Published: (2025-01-01) -
Immune Checkpoint Blockade in Melanoma – Earlier is Better?
by: Vincas Urbonas, et al.
Published: (2024-09-01) -
Bibliometric insight into neoadjuvant immunotherapy in non-small cell lung cancer: trends, collaborations, and future avenues
by: Pengliang Xu, et al.
Published: (2025-02-01)